These results are consistent with human clinical data where APOE4 carriers exhibit significantly higher amyloid plaque deposition and APOE2 carriers exhibit significantly lower amyloid deposition than AD patients with APOE3/APOE3 genotypes [19, 92]. The gene discussed is APOE; the disease is Alzheimer disease.